[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353385-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353385-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cdk10-loss-primes-tumor-cells-for-transcriptional-vulnerability-and-sensitizes-to-cdk1213-inhibition","CDK10 loss primes tumor cells for transcriptional vulnerability and sensitizes to CDK12/13 inhibition","","CDK12 and CDK13 are emerging therapeutic targets in epithelial cancers because they support transcriptional elongation and preserve genomic stability. Lack of predictive biomarkers limits clinical use of CDK12/13 inhibitors. A genome-wide CRISPR-Cas9 screen identifies CDK10 loss as a consistent, kinase-dependent enhancer of sensitivity to the selective inhibitor CTX-439. Functional tests in multiple cancer cell and xenograft models show that CDK10 deficiency amplifies apoptotic responses and extends CTX-439-induced transcriptional suppression by delaying RNA polymerase II re-engagement. This supports CDK10 as a biomarker for patient stratification and a co-target to strengthen transcriptional cancer therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cdk10-loss-primes-tumor-cells-for-transcriptional-vulnerability-and-sensitizes-to-cdk1213-inhibition/353385/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cdk10-loss-primes-tumor-cells-for-transcriptional-vulnerability-and-sensitizes-to-cdk1213-inhibition/353385.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are CDK12/13 considered therapeutic targets in epithelial cancers?","Question",{"text":63,"@type":64},"CDK12/13 maintain transcription-associated phosphorylation states needed for efficient expression of long genes, including DNA damage response genes, thereby supporting genome stability and cell survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What biomarker-like finding does the study report for sensitivity to CDK12/13 inhibitors?",{"text":68,"@type":64},"Genome-wide CRISPR-Cas9 screening identifies CDK10 loss as a top-ranked enhancer of response to the selective CDK12/13 inhibitor CTX-439.",{"name":70,"@type":61,"acceptedAnswer":71},"How does CDK10 loss increase the effect of CTX-439 mechanistically?",{"text":72,"@type":64},"CDK10 loss extends the duration of CTX-439-induced transcriptional suppression and delays RNA polymerase II re-engagement at sensitive gene loci, leading to stronger antitumor responses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353385,1790186077,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nCDK10 loss primes tumor cells for transcriptional vulnerability and sensitizes to CDK12/13 inhibition  \nShaﬁqul Islam1,2, Yusuke Tarumoto 1, Mariko Takano1, Seiichi Sugino1, Gohei Nishibuchi 1, Akio Mizutani3, Hiroko Yamakawa 3, Daisuke Morishita3 and Kosuke Yusa 1 ✉  \n© The Author(s) 2026  \n\n|  | CDK12 and CDK13, two transcriptional cyclin-dependent kinases (CDKs), are emerging as therapeutic targets in epithelial cancers due to their vital roles in transcriptional elongation and maintaining genomic stability. However, the absence of predictive biomarkers may impede the clinical use of CDK12/13 inhibitors. Here, we identify CDK10 as a consistent and kinase-dependent regulator of sensitivity to CDK12/13 inhibition. A genome-wide CRISPR-Cas9 screen across six breast and ovarian cancer models reveals CDK10 loss as a top-ranked enhancer of response to the selective CDK12/13 inhibitor CTX-439 . Functional validation in multiple cancer cell lines and xenograft models shows that CDK10 deﬁciency boosts apoptotic responses and increases the antitumor effects of CDK12/13 inhibition. Mechanistically, CDK10 loss extends the duration of CTX-439-induced transcriptional suppression and delays RNA polymerase II re-engagement at sensitive gene loci, exempliﬁed by CAPN7 and SENP6 . These ﬁndings indicate CDK10 as a probable biomarker for patient stratiﬁcation and as a co-target to boost the efﬁcacy of transcriptional therapies. Our work reveals a previously underappreciated role for CDK10 in transcriptional resilience, emphasizing its potential to guide and |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| enhance CDK12/13-based cancer treatments. |  |  |\n|  | Cell Death and Disease (2026) 17:737 ; [https://doi.org/10.1038/s41419-026-08973-x](https://doi.org/10.1038/s41419-026-08973-x) |  |\n|  |  |  |\n\nINTRODUCTION  \nCyclin-dependent kinases (CDKs) integrate control of cell division and transcription, and their dysregulation is a recurrent feature of human cancers [1–3] . Within the transcriptional arm of this family, different CDKs act sequentially on the RNA polymerase II (Pol II) carboxy-terminal domain (CTD) to drive distinct stages of the transcription cycle. CDK7 phosphorylates Ser5 and Ser7 to promote initiation and establish promoter-proximal pausing, CDK9 phosphorylates Ser2 (S2) to release Pol II into productive elongation, and CDK12/13 maintain S2 phosphorylation across gene bodies to ensure efﬁcient transcription of long, structurally complex genes [4–6] . Sustained S2 phosphorylation by CDK12/13 is therefore critical for the full-length transcription of DNA damage response (DDR) genes including BRCA1, BRCA2, ATR, and FANCD2, thereby safeguarding genome stability and cellular survival [7, 8] . Given their role in DDR and genomic stability, CDK12/13 have emerged as attractive therapeutic targets in cancer, particularly in tumors that retain homologous recombination (HR) proﬁciency [9] . Pharmacological inhibition of CDK12/13 disrupts transcriptional elongation of DDR genes, inducing a “BRCAness” phenotype [10, 11] . This phenotype, characterized by a defect in DNA repair similar to that seen in BRCA-mutated tumors, sensitizes HRproﬁcient cells to PARP inhibition or replication stress-inducing agents [12–15] . Inducing this phenotype represents a principal mechanism through which CDK12/13 inhibitors achieve therapeutic efﬁcacy [16] . Several selective CDK12/13 inhibitors, such as  \nTHZ531, SR-4835, and CTX-439 we developed [17], have demonstrated efﬁcacy in preclinical models by inducing apoptotic cell death through transcriptional catastrophe mainly [10, 11, 17, 18] . However, clinical translation of CDK12/13 inhibitors may face key challenges, particularly in the absence of predictive biomarkers that can stratify responsive patients [16, 19–21] . Unlike PARP inhibitors, whose developm","cbCaiaXMW9TSiutG","https://ap.wps.com/l/cbCaiaXMW9TSiutG","pdf",5002592,13,"English","# Introduction\n## CDK12/13 as transcriptional CDKs and therapeutic targets\n## Need for predictive biomarkers and current limitations\n## CDK10 biology and rationale for investigation","[{\"question\":\"Why are CDK12/13 considered therapeutic targets in epithelial cancers?\",\"answer\":\"CDK12/13 maintain transcription-associated phosphorylation states needed for efficient expression of long genes, including DNA damage response genes, thereby supporting genome stability and cell survival.\"},{\"question\":\"What biomarker-like finding does the study report for sensitivity to CDK12/13 inhibitors?\",\"answer\":\"Genome-wide CRISPR-Cas9 screening identifies CDK10 loss as a top-ranked enhancer of response to the selective CDK12/13 inhibitor CTX-439.\"},{\"question\":\"How does CDK10 loss increase the effect of CTX-439 mechanistically?\",\"answer\":\"CDK10 loss extends the duration of CTX-439-induced transcriptional suppression and delays RNA polymerase II re-engagement at sensitive gene loci, leading to stronger antitumor responses.\"}]","CDK10 loss primes tumor cells for transcriptional vulnerability and sensitizes to CDK12/13 inhibition | PDF",1790105038,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40a5bbf3d4a8a0ca0706754b6d847c3e.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/affbe59f9b20365063f0f6aee9574c1a.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f9641eebeea455d33c241cf048e45ac.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e4461303ddc869cf95363d82d84c900.webp",980,1301]